Personalized Gene Editing to Treat an Inborn Error of Metabolism | NEJM
In this editorial, the authors describe the foundations of an N-of-1 gene-editing study to treat an infant with a urea-cycle disorder.
Related Articles
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer | NEJM
Hereditary leiomyomatosis and renal-cell cancer (HLRCC) is an inherited disorder characterized by germline pathogenic variants in the gene encoding fumarate hydratase and an increased risk…
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer | NEJM
The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell…
Unruptured Intracranial Aneurysms | NEJM
Intracranial aneurysms are common, and the risk of rupture is influenced by size, location, morphology, and factors such as hypertension, smoking, and family history. Management…
Unruptured Intracranial Aneurysms | NEJM
Intracranial aneurysms are common, and the risk of rupture is influenced by size, location, morphology, and factors such as hypertension, smoking, and family history. Management…
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer | NEJM
The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell…
Ebola and a Decade of Disparities — Forging a Future for Global Health Equity | NEJM
Since the 2014–2016 West African Ebola outbreak, there have been numerous proposals and promises to reform global health infrastructure. Yet inequity remains deeply entrenched.
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer | NEJM
Hereditary leiomyomatosis and renal-cell cancer (HLRCC) is an inherited disorder characterized by germline pathogenic variants in the gene encoding fumarate hydratase and an increased risk…
Midyear Roundup: FDA’s Novel Oncology Drug Approvals in 2025
In the first half of 2025, the FDA approved 7 novel drugs for oncologic conditions, including for non-small cell lung cancer; ovarian cancer; and metastatic,…
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer | NEJM
The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell…
Expert: Individualized Gender-Affirming Care and Support is Essential for LGBTQ+ Patients
Creating a supportive environment and staying informed on the latest research can be significant when supporting patients in the LGBTQ+ community, notes Olivia Buckoski, PharmD,…